1Attal M, Harousseau L, Stoppa AM, et al. A prospective,randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med, 1996,335:91-97. 被引量：1
2Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood, 2004,103:20-32. 被引量：1
3Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m^2 melphalan and 8 Gy total body irradiation plus 140 mg/m^2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial.Blood ,2002,99 : 731-735. 被引量：1
4Palumbo A, Bringhen S, Petricci MT, et al. Intermediate-dose melphalan improves survival of mydoma patients aged 50 to 70:results of a randomized controlled trial. Blood, 2004,104 : 3052-3057. 被引量：1
5Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood, 1998, 92: 3131-3136. 被引量：1
6Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med, 2003,349 : 2495 -2502. 被引量：1
7Cavo M, Zamagni E, Cellini C, et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience.Hematol J ,2003, 4( Suppl 1 ) : S60. 被引量：1
8Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy ensure long-term survival in myeloma treated with Total Therapy Ⅰ: interpretation in the context of global gene expression. Blood, 2003, 101:3849-3856. 被引量：1
9Jacobson J, Barlogie B, Shaughnessy J, et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS) : only 13% 1-year survival despite tandem transplants. Br J Haematol,2003,122:430-440. 被引量：1
10Barlogie B, Kyle R, Anderson K, et al. Comparable survival in multiple myeloma(MM) with high dose therapy (HDT) employing MEL 140 mg/m^2 + TBT 12Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN)maintenance : results of intergroup trial S9321. Blood, 2003, 102 :42a. 被引量：1
